Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed exercised employee stock options and sold shares in a planned transaction. She exercised options for 10,000 shares of common stock at $15.46 per share and then sold 10,000 shares at $30.00 per share on the same day. After these transactions, she directly holds 105,211 shares of Travere Therapeutics common stock. The filing notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements, and that the underlying stock option grant from January 31, 2020 is fully vested and exercisable.
TVTX filed a Form 144 disclosing the intended sale of 60,000 shares of Common Stock on 04/01/2026. The filing lists the sale method as cash and records several prior dispositions in the past three months: 8,135; 51,865; 100,087; and 60,000 shares on specified dates.
Elizabeth Reed reported the proposed sale of 10,000 shares of Common Stock under Form 144, linked to a stock option exercise dated 04/01/2026. The filing lists multiple earlier dispositions in 2026: 10,000 shares on 03/16/2026 for $280,861.00, 10,000 on 02/17/2026 for $278,317.00, and other smaller sales in February and January.
Travere Therapeutics Inc ownership filing shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries and divisions to report holdings separately in reliance on SEC Release No. 34-39538.
Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026. The filing also lists prior dispositions by Ms. Reed in the past three months: $278,317.00 for 10,000 shares on 02/17/2026, $96,360.09 for 2,994 shares on 02/04/2026, $230,463.88 for 7,175 shares on 02/03/2026, and $273,420.00 for 10,000 shares on 01/20/2026.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised stock options for 60,000 shares on February 20, 2026, converting an employee stock option into common stock at an exercise price of $15.4600 per share. He then sold 60,000 common shares in an open-market transaction at a weighted average price of $30.0961, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, his directly held common stock position was 432,886 shares.
TVTX filing: a Form 144 notice reports proposed sales of common shares by an affiliate and by Eric M. Dube. The filing lists an affiliate sale of 60,000 shares on 02/20/2026 (option originally granted 01/31/2020), and three recent sales by Eric M. Dube: 8,135, 51,865, and 100,087 shares on 01/23/2026, 01/27/2026, and 02/03/2026, respectively, with cash consideration shown.
Travere Therapeutics files its annual report describing a rare‑disease focused biopharma business built around FILSPARI and a growing pipeline. The company now has full FDA approval for FILSPARI to slow kidney function decline in adults with IgA nephropathy and is pursuing an additional indication in focal segmental glomerulosclerosis, with a supplemental application under FDA review and an April 13, 2026 PDUFA date.
Travere is also advancing pegtibatinase in a pivotal Phase 3 trial for classical homocystinuria after resolving manufacturing scale‑up issues and restarting enrollment in 2026. Existing revenue comes from rare kidney and metabolic products, including Thiola/Thiola EC, though these face generic competition. Globally, Travere relies on partners CSL Vifor and Chugai for FILSPARI commercialization outside the United States and highlights extensive patent and orphan‑drug exclusivity intended to protect key assets.
Travere Therapeutics, Inc. executive Elizabeth E. Reed, the Chief Legal Officer and General Counsel, reported option exercises and share sales in Travere stock. On February 17, 2026, she exercised an employee stock option for 10,000 shares, acquiring the same number of Travere common shares at a reported exercise price of $19.08 per share. The option, granted on January 4, 2017 and expiring on January 4, 2027, is fully vested and exercisable. On the same date, she sold 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262, in each case under a prearranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, she directly owns 105,211 shares of Travere common stock.